The total trade value of SCO Member States has increased nearly 100 times over the past 20 years

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Hypershell (极壳科技) Secures $50 Million Series B+ Funding Co-Led by Ant Group (蚂蚁集团) and Meituan Dragonball Capital (美团龙珠), Accelerating Global Expansion of Consumer-Grade Exoskeletons

Consumer-grade exoskeleton startup Hypershell (极壳科技) announced the completion of its $50 million Series B+ financing round co-led by Ant Group (蚂蚁集团) and Meituan DragonBall (美团龙珠), bringing its total Series B series funding to $120 million to accelerate its global leadership in human-augmentation robotics.

Unpacking China | Key Chinese Firms to Watch This Week （10/05/2026-16/05/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

"Bowintec" completed a Pre-A financing round of nearly 300 million RMB, accelerating the large-scale implementation of industrial embodied intelligence.

Boyuan Capital, the market-oriented investment platform under Bosch, and GalaxyBot, a leading company in embodied intelligence, jointly incubated a joint venture — Bowintec (博银合创), which announced the completion of a Pre-A financing round, raising nearly 300 million RMB.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.